Capricor Therapeutics rises 12.8% after positive Duchenne drug data
Capricor Therapeutics shares rose 12.8% to $9.67 after 24-month open-label extension data from its Duchenne drug trial was presented at the World Muscle Society Congress. B. Riley Securities maintained a "buy" rating and $21 price target, stating the data strengthens the case for approval.